Edwards Lifesciences announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 and simultaneously… read more.
GSK plc announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of Menveo (Meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine)… read more.
Zai Lab and Pfizer announced a strategic collaboration for the novel antibacterial drug Xacduro (sulbactam-durlobactam) in mainland China. Pfizer’s affiliated companies will be exclusively authorized to undertake and… read more.
NICE (UK) 1.1Teclistamab is recommended as an option for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory… read more.
Medtronic plc announced FDA clearance for its new InPen app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera… read more.
Bayer announced that the FDA has accepted the company’s supplemental new drug application (sNDA) for the oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) in combination with androgen deprivation… read more.
Autolus Therapeutics plc an early-commercial stage biopharmaceutical company developing next-generation programmed T cell therapies, announces the FDA has granted marketing approval for Aucatzyl (obecabtagene autoleucel) for the… read more.
Boston Scientific Corporation announced positive three-year primary endpoint results from the OPTION global clinical trial of the Watchman FLX Left Atrial Appendage Closure (LAAC) Device. Key findings from… read more.
Royal Philips, a global leader in health technology, announced its next-generation 1.5T BlueSeal MR wide-bore scanner will be unveiled at RSNA 2024. The latest generation scanner features a… read more.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on the results from the LAURA Phase III trial,… read more.
Azurity Pharmaceuticals announced that the FDA has approved Danziten, the first and only nilotinib with no mealtime restrictions indicated for adult patients with newly diagnosed Philadelphia chromosome positive… read more.
PTC Therapeutics, Inc. announced the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever gene therapy approved in the United States that… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
